Recce Pharmaceuticals (RCE) Investor Update summary

Executive summary and commercial highlights

• Advancing a new class of synthetic antibiotics, recognized by WHO as the most advanced in over 40 years.

• Late-stage Phase III trials for diabetic foot ulcer infections in Indonesia and Australia, with expedited regulatory review and near-term commercial potential.

• Strong bilateral support from Indonesian and Australian governments, and a memorandum of understanding with a leading Indonesian pharmaceutical company for distribution.

• Large addressable markets in ASEAN and globally, with diabetic foot ulcer and sepsis markets valued at billions annually.

• Manufacturing is in-house, cost-effective, and supported by a robust patent portfolio extending to 2041.

Clinical development and data

• Phase II studies showed 93% positive clinical response in ABSSSI and high efficacy in diabetic foot ulcer infections.

• Phase III trial in Indonesia targets up to 300 patients, with interim data expected in Q1 next year and potential approval within 60 days post-submission.

• Parallel Phase III study in Australia, with both studies designed to support global regulatory submissions.

• No resistance observed in tested bacteria, with rapid bactericidal action demonstrated in clinical and in vitro studies.

• Special Access Scheme cases in Australia showed successful treatment of patients unresponsive to existing therapies.

Financial and capital update

• Equity raise of AUD 15 million at AUD 0.28 per share, open to all shareholders, with strong director participation.

• Additional non-dilutive funding expected from R&D advances and rebates, targeting a total cash position of up to AUD 35 million.

• Funds allocated to two Phase III studies, regulatory submissions, and U.S. Department of Defense collaborations.

• No debt, with top 20 shareholders holding 50% of equity.